NASDAQ:SGHT Sight Sciences Q3 2026 Earnings Date & Estimates $9.02 +0.03 (+0.33%) Closing price 04:00 PM EasternExtended Trading$9.02 +0.00 (+0.04%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Sight Sciences is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 4, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Sight Sciences in Q3 2026Sight Sciences is expected to post earnings of -$0.12 per share on revenue of $23.51 million. In the same quarter a year earlier Sight Sciences reported -$0.16 per share on revenue of $19.91 million. Sight Sciences last reported on August 5, 2026, posting -$0.08 per share and beating the -$0.1833 consensus estimate. Sight Sciences has beaten the consensus EPS estimate in 6 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.12Expected Revenue$23.51 millionPrior-Year EPS-$0.16Prior-Year Revenue$19.91 millionExpected Revenue Growth+18.1%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.08 (Beat by +$0.1033)Last Quarter Revenue$23.39 millionEPS Beat Rate6 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Sight Sciences Q3 2026 Earnings FAQ When does Sight Sciences report Q3 2026 earnings? Sight Sciences (NASDAQ:SGHT) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Sight Sciences' Q3 2026 earnings call? Sight Sciences' Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Sight Sciences? Analysts expect Sight Sciences to post earnings of -$0.12 per share for Q3 2026. How much revenue is Sight Sciences expected to report? The consensus revenue estimate for Sight Sciences is $23.51 million for Q3 2026. Sight Sciences Earnings HeadlinesSight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026October 21, 2026 | globenewswire.comHC Wainwright Weighs in on Sight Sciences Q3 EarningsOctober 19, 2026 | americanbankingnews.comWhy Some AI Stocks Already Surged Over 300 PercentJason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run, and Vertiv before a 1900 percent run. Now he's tracking a radical light-speed technology that could make AI 100 times faster and 100 times more energy efficient. Stocks tied to it have already climbed 133 percent, 217 percent, and 320 percent.October 26 at 1:00 AM | Brownstone Research (Ad)HC Wainwright Begins Coverage on Sight Sciences (NASDAQ:SGHT)October 17, 2026 | americanbankingnews.comHC Wainwright & Co. initiates coverage of Sight Sciences with buyOctober 15, 2026 | msn.comHC Wainwright Initiates Coverage on Sight Sciences With Buy Rating, $14 Price TargetOctober 15, 2026 | marketscreener.comMSee More Sight Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sight Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sight Sciences and other key companies, straight to your email. Email Address About Sight SciencesSight Sciences (NASDAQ:SGHT) is an ophthalmic medical technology company focused on developing and commercializing products designed to address the underlying causes of certain eye diseases. The company’s portfolio is centered on minimally invasive and non-invasive procedures intended to improve patient outcomes while supporting physicians in the treatment of glaucoma and ocular surface disease. Its primary products include the OMNI Surgical System, a minimally invasive glaucoma surgery device used to reduce intraocular pressure by improving the eye’s natural fluid outflow pathways, and the TearCare System, a thermal pulsation technology designed to treat meibomian gland dysfunction, a common cause of evaporative dry eye disease. Sight Sciences markets its products primarily to ophthalmologists and other eye-care professionals. Founded in 2010 and headquartered in Menlo Park, California, Sight Sciences serves the United States and select international markets through direct commercial operations and distribution relationships. The company’s products are intended to provide alternatives or complements to traditional pharmaceutical and surgical approaches in glaucoma and dry eye care.View Sight Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Anthropic's IPO Filing Reveals a Massive Opportunity for AI Infrastructure GiantsBristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own StockBuy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big CatalystsComfort Systems Earnings: AI Slowdown or More Growth Ahead?MarketBeat Week in Review – 10/19 - 10/23Amex Stock Slides on Job Cuts, But the Real Story Is MacroBloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline Upcoming Earnings Hilton Worldwide (10/27/2026)Royal Caribbean Cruises (10/27/2026)CocaCola (10/27/2026)Baker Hughes (10/27/2026)ONEOK (10/27/2026)Robinhood Markets (10/27/2026)HSBC (10/27/2026)S&P Global (10/27/2026)Visa (10/27/2026)HCA Healthcare (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
